Enprofylline
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317774

CAS#: 41078-02-8

Description: Enprofylline is a xanthine derivative used in the treatment of asthma, which acts as a bronchodilator. It acts primarily as a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine receptor antagonist. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.

Chemical Structure

img
Enprofylline
CAS# 41078-02-8
Instruction

Theoretical Analysis

MedKoo Cat#: 317774
Name: Enprofylline
CAS#: 41078-02-8
Chemical Formula: C8H10N4O2
Exact Mass: 194.08
Molecular Weight: 194.190
Elemental Analysis: C, 49.48; H, 5.19; N, 28.85; O, 16.48

Price and Availability

Size Price Availability Quantity
10mg USD 250 2 weeks
25mg USD 450 2 weeks
50mg USD 750 2 weeks
Bulk inquiry

Synonym: Enprofylline; 3-Propylxanthine; 3-n-Propylxanthine; Enprofyllinum; Enprofilina; 3-propylxanthine; enprofylline;

IUPAC/Chemical Name: 3-propyl-7H-purine-2,6-dione

InChi Key: SIQPXVQCUCHWDI-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)

SMILES Code: CCCN1C2=C(C(=O)NC1=O)NC=N2

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 194.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mojsilovic-Petrovic J, Arneja A, Kalb RG. Enprofylline protects motor neurons
from in vitro excitotoxic challenge. Neurodegener Dis. 2005;2(3-4):160-5. PubMed
PMID: 16909021.


2: Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8
secretion in human mast cells. An enprofylline-sensitive mechanism with
implications for asthma. J Clin Invest. 1995 Oct;96(4):1979-86. PubMed PMID:
7560091; PubMed Central PMCID: PMC185836.


3: Chapman KR, Ljungholm K, Kallen A. Long-term xanthine therapy of asthma.
Enprofylline and theophylline compared. International Enprofylline Study Group.
Chest. 1994 Nov;106(5):1407-13. PubMed PMID: 7956392.


4: Nadai M, Hasegawa T, Wang L, Tagaya O, Nabeshima T. Alterations in the
pharmacokinetics and protein binding of enprofylline in Eisai hyperbilirubinemic
rats. Drug Metab Dispos. 1994 Jul-Aug;22(4):561-5. PubMed PMID: 7956730.


5: David-Wang AS, Scarth B, Freeman D, Chapman KR. A rapid monoclonal antibody
blood theophylline assay; lack of cross-reactivity with enprofylline. Ther Drug
Monit. 1994 Jun;16(3):323-6. PubMed PMID: 8085286.


6: Muraoka I, Hasegawa T, Nadai M, Wang L, Tagaya O, Nabeshima T. Influence of
age on the disposition and renal handling of enprofylline in rats. J Pharm
Pharmacol. 1994 Mar;46(3):230-4. PubMed PMID: 8027934.


7: Nadai M, Hasegawa T, Kato K, Wang L, Nabeshima T, Kato N. The disposition and
renal handling of enprofylline in endotoxemic rats by bacterial
lipopolysaccharide (LPS). Drug Metab Dispos. 1993 Jul-Aug;21(4):611-6. PubMed
PMID: 8104119.


8: Barlinski J, Lockhart A, Frossard N. Modulation by theophylline and
enprofylline of the excitatory non-cholinergic transmission in guinea-pig
bronchi. Eur Respir J. 1992 Nov;5(10):1201-5. PubMed PMID: 1486966.


9: Nadai M, Hasegawa T, Muraoka I, Takagi K, Nabeshima T. Dose-dependent
pharmacokinetics of enprofylline and its renal handling in rats. J Pharm Sci.
1991 Jul;80(7):648-52. PubMed PMID: 1941561.


10: Youngchaiyud P, Charoenratanakul S, Nana A, Wong E, Laxmyr L, Bamberg P.
Intravenous enprofylline in the treatment of patients with acute asthma. J Int
Med Res. 1990 Nov-Dec;18(6):473-82. PubMed PMID: 2292329.


11: Chapman KR, Boucher S, Hyland RH, Day A, Kreisman H, Rivington R, Hodder RV,
York EL, Abboud RT, Peters S, et al. A comparison of enprofylline and
theophylline in the maintenance therapy of chronic reversible obstructive airway
disease. J Allergy Clin Immunol. 1990 Feb;85(2):514-21. PubMed PMID: 2406328.


12: Koëter GH, Kraan J, Boorsma M, Jonkman JH, van der Mark TW. Effect of
theophylline and enprofylline on bronchial hyperresponsiveness. Thorax. 1989
Dec;44(12):1022-6. PubMed PMID: 2694418; PubMed Central PMCID: PMC1020878.


13: Chapman KR, Bryant D, Marlin GE, Mitchell C, Ruffin R, Inouye T, Pedersen B,
Koskinen S, Osen SS, Ringdal N, et al. A placebo-controlled dose-response study
of enprofylline in the maintenance therapy of asthma. Am Rev Respir Dis. 1989
Mar;139(3):688-93. PubMed PMID: 2647007.


14: Persson CG, Andersson PT, Gustafsson B. Budesonide reduces sensitivity to
antigen but does not alter baseline tone or responsiveness to carbachol,
terbutaline, and enprofylline in IgE-sensitized guinea-pig tracheae. Int Arch
Allergy Appl Immunol. 1989;88(4):381-5. PubMed PMID: 2722258.


15: Chapman BJ, McDonald C, Capewell S, Frame MH, Crompton GK. Enprofylline in
chronic asthma. Br J Dis Chest. 1988 Oct;82(4):354-9. PubMed PMID: 3076790.


16: Hsieh JY, Thornton TJ, Bayne WF. High-performance liquid chromatographic
determination of enprofylline in human plasma. J Chromatogr. 1988 Aug
19;430(1):175-9. PubMed PMID: 3215954.


17: Laursen LC, Borgå O, Ljungholm K, Weeke B. Transfer of enprofylline into
breast milk. Ther Drug Monit. 1988;10(2):150-2. PubMed PMID: 3381231.


18: Kraan J, Jonkman JH, Koëter GH, Gips CH, de Jong PE, van der Mark TW, Ekman
I, de Zeeuw RA. The pharmacokinetics of theophylline and enprofylline in patients
with liver cirrhosis and in patients with chronic renal disease. Eur J Clin
Pharmacol. 1988;35(4):357-62. PubMed PMID: 3197743.


19: Maxwell DL, Fuller RW, Conradson TB, Dixon CM, Aber V, Hughes JM, Barnes PJ.
Contrasting effects of two xanthines, theophylline and enprofylline, on the
cardio-respiratory stimulation of infused adenosine in man. Acta Physiol Scand.
1987 Nov;131(3):459-65. PubMed PMID: 3425350.


20: Murciano D, Aubier M, Viirès N, Mal H, Pariente R. Effects of theophylline
and enprofylline on diaphragmatic contractility. J Appl Physiol (1985). 1987
Jul;63(1):51-7. PubMed PMID: 3624149.